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Abstract
Preclinical studies of veterinary medicinal products are important and compulsory studies in the development of new dosage 
forms. The aim of preclinical research is to determine the toxic effect and therapeutic efficacy of the test substance-the future dosage 
form, its effect on the body’s basic systems, as well as the identification of possible side effects.
This work is part of the research on the development of the composition and technology of the veterinary drug – a solution 
for intramammary application, conventionally called “Argocide”, intended for the treatment of mastitis in cattle.
A study of the acute toxicity of the intramammary veterinary drug was carried out in experiments on white rats of both sexes, 
according to the requirements for potential medicines. The establishment of the value of the average lethal dose (LD50) of the veteri-
nary drug “Argocide” with intramuscular single administration to white mature rats is impossible due to the absence of animal death 
even when the drug is administered at doses exceeding 5.0 ml/kg. This experiment allows the veterinary preparation “Argocide” to 
be classified as practically non-toxic compounds (V class).
The analysis of the results of the conducted studies indicates the relative harmlessness of the potential drug for veterinary 
medicine and allows us to foresee that the “Argocide” preparation can be classified as low-risk substances, which justifies the expe-
diency of its further study and introduction into practice.
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1. Introduction
Preclinical studies of veterinary medicinal products are important and compulsory 
studies in the development of new dosage forms, especially in the context of the implementa-
tion of the legislation on the control of chemical compounds adopted by member countries of 
the Organization for Economic Co-operation and Development. First of all, this concerns the 
implementation of a scrupulous assessment of the potential hazard in conditions of guaranteed 
quality [1]. The aim of preclinical research is to determine the toxic effect and therapeutic 
efficacy of the test substance – the future dosage form, its effect on the body’s basic systems, 
as well as the identification of possible side effects. The implementation of the rules of GLP 
system fully guarantees the quality of innovative medicinal veterinary drugs, their high ther-
apeutic effectiveness [2, 3].
At the initial stage, primary toxicological studies and pharmacological evaluation of 
new active pharmaceutical ingredients, their separate components, various forms of new vet-
erinary preparations are carried out, which not only determine the successful development 
of further experimental, clinical research and practical developments, but also has a decisive 
influence on the possibility of creating a highly efficient competitive and a low-toxic drug. 
Meeting the requirements of GLP provides a rationale for the safety of pharmaceutical devel-
opment of a veterinary drug [4].
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This work is a continuation of the research on the development of the composition and tech-
nology of a veterinary drug – a solution for intramammary administration under the conventional 
name “Argocide” [5, 6]. The developed combined medicinal product is intended for the treatment 
of subclinical inflammation of the mammary gland (mastitis) in agricultural animals, in particular 
in cattle [7].
Mastitis is an inflammation of the mammary gland that occurs in response to the influence 
of unfavourable environmental factors, in conditions of a decrease in the resistance of the organism 
and the complication of the infection. Inflammation of the mammary gland leads to a decrease 
in milk production, changes in the chemical composition, physical and biochemical properties of 
milk, as a result of which it loses nutritional value, technological properties, which affects its qual-
ity and safety [8]. The course and consequences of mastitis depend not only on the localization 
of the process and the virulence of the pathogen, but also on the immunobiological status of the 
whole animal’s organism and the reactivity of the breast tissue [9, 10]. The development of the in-
flammatory process in the mammary gland occurs as a result of the action of mechanical, physical, 
chemical and biological factors. In particular, the biological factor accounts for 85 % of all cases 
of mastitis [11].
The spread of mastitis is explained by physiological loads on the organism of highly 
productive cows, inaccuracies in keeping and feeding, as well as non-observance of veteri-
nary-sanitary requirements. To date, preparations based on antibiotics remain the main group 
for treating patients with mastitis of animals [12, 13]. However, the massive use of antibiot-
ics for the treatment of mastitis has revealed a number of negative factors: the emergence of 
antibiotic-resistant strains of microorganisms; development of dysbacteriosis and decreased 
immune status; the presence of antibiotics in milk after the termination of the course of anti-
biotic therapy and as a consequence, the emergence of unwanted reactions in people who con-
sume such milk [14]. One solution to the problem of dairy cattle disease is the pharmaceutical 
development of innovative veterinary drugs with antimicrobial substances that do not cause 
resistance. 
2. Aim of the research
Study of acute toxicity of test specimens of a combined veterinary preparation under the 
conventional name “Argocide”, a solution for intracisternal administration, with intramuscular in-
jection of mature white rats.
3. Materials and methods 
The research was carried out at the Institute of Pharmacology and Toxicology of the Na-
tional Academy of Medical Sciences of Ukraine. Experiments in which animals were used was 
conducted in accordance with the international requirements for the humane treatment of animals 
and compliance with the requirements of Directive 86/609/EEC regarding the protection of animals 
[15, 16]. All experimental animals were kept in standard sanitary conditions. During the experi-
ment, the animals were kept in a vivarium at 20–24 oC, humidity 30–70 % natural light mode “day-
night”, standard cells, with a balanced diet.
Investigation of acute toxicity of intramammary veterinary preparation was carried out in 
experiments on white non adult rats of both sexes (24–12 each sex; 2 animals at each of the inves-
tigated doses; 6 control animals (3 of each sex), according to the requirements of potential drug 
[1, 17]. The drug in the dosage form of solution for intracisternal administration was administered 
at varying doses – from 2.0 to 6.3 ml/kg at intervals – once daily [18] The volume of liquid which is 
injected animals. did not exceed volumes defined by the rules of pre-clinical research of drugs [2] 
The separate group of animals (control) they were treated with solvent (vehicle) preparation – water 
for injection, in a volume of 1.5 ml intramuscularly.
The duration of observation of the state of the animals after a single administration 
of “Argocide” in a drug form for intracisternal administration was 14 days. Observation of 
clinical signs of toxicity and death of the animals was carried out on the first day after ad-
ministration of the veterinary drug continuously for one hour, and then at 2, 3, 5 hours after 
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administration. Over the next 14 days, each animal was observed daily, twice a day in 1000 and 
in 1700. We registered cases of appearance and/or disappearance of clinical signs of toxicity, 
including – animal deaths.
The individual body weight of the animals was recorded before 1000 before the administra-
tion of the drug, and then 3, 7 and 14 days after the administration of the drug “Argocide”. Changes 
in body weight were calculated in comparison with the weight on the day of administration and the 
body weight of the animals in the control groups.
Macroscopy. 14 days after the administration of the drug, all animals were withdrawn from 
the experiment by euthanasia by cervical dislocation under light ether anesthesia. All animals were 
subject to complete external examination, autopsy taking into account registered clinical disorders 
and detailed examination of internal organs. Before euthanasia at the end of the experiment, all 
animals were starving for 3 hours. It was planned to conduct a macroscopic study of animals that 
may die, immediately after the fact of death was established or the next morning (in 1100), if the 
animal died at night.
Weight of organs. The following organs were weighed: liver, kidneys, spleen, lungs, and 
heart. Paired organs were weighed together. The relative mass of organs was calculated in g per 
100 g of body weight.
Statistical processing of data. The data are given as mean ± mean error (M±m). Statisti-
cal processing of data was performed using of the Student t-test. The changes were considered 
statistically significant at p<0.05. For the statistical processing of data, the MS Excel program 
was used [19, 20].
5. Results of the research
The degree of acute toxicity of the drug is characterized by a dose value, one-time (or mul-
tiple for 1 day) administration of which causes the death of 50 % of animals (LD50).
The main criterion for the toxic effect of the drug was the death of animals. At the same 
time, data on possible dose-dependent effects of the drug on various body functions were recorded 
in animals for 14 days, namely: the individual body weight of animals, general condition, changes 
in body position, skin condition, color of mucous membranes, body temperature (rectal), presence/
lack of miosis/mydriasis, lacrimation, salivation, rhinorrhea, changes in the color of urine and 
feces and their frequency, drowsiness, tremors, convulsions, piloerection, cardiovascular, central 
nervous and respiratory activity system.
The results of changes in body mass and body temperature (M±m) in sexually mature 
white rats after a single intramuscular injection of the “Argocide” preparation are presented 
in Table 1.
Table 1
The dynamics of mass and body temperature (M ± m) in mature white rats after a single intramuscular 
injection of the drug “Argocide” in a dose of 6.3 ml/kg. 
Group
Time of observation, (days)
Initial data 3 days 7 days 14 days
Control, weight, g (n=6) 182.6±1.08 187.3±1.60 192.8±1.95* 197.1±1.13*
Control, temperature, ºС (n=6) 38.1±0.14 37.9±0.16 37.9±0.13 38.0±0.14
Experiment, weight, g (n=24) 181.2±2.2 190.2±2.45 195.1±1.95* 199.8±2.4*
Experiment, temperature, ºС (n=6) 38.1±0.11 38.4±0.12 38.4±0.12 38.2±0.10
Note: * – p <0.05 relative to the original data
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When administered intramuscularly to white rats, the drug “Argocide” in a dosage form is 
a solution for intracisternal administration (applied at doses of 3.16 ml/kg body weight of the an-
imal and higher), the rats displayed certain clinical signs of intoxication, namely: cell congestion, 
decreased motor activity and reactions to external stimuli, which were noted immediately after the 
administration of the drug, as well as during the day of observation. Slowing down movements and 
violation of coordination of movements (ataxia) were noted during the first two hours after a single 
injection of the drug.
More active motor reactions were observed only 3–5 hours after the administration of the 
drug, ataxia was no longer noted at this time, while extension of the hind limbs during movement 
in the cage was observed simultaneously within 1 day after the introduction of the “Argocide”. 
By the third day after the administration of the preparation, the animals had an untidy appear-
ance, which was exuded in appearance – a damp coat, but the consumption of food and water 
was usual. Other signs of intoxication – seizures, tremors, salivation, changes in respiratory rate, 
cyanosis of the visible mucous membranes, blepharospasm, lateral position, etc. – in animals 
were not noted.
After 3 days after intramuscular administration of the drug “Argocide”, no clinical 
signs of intoxication were observed: animals willingly consumed food and water, reactions 
to external stimuli were common, animals actively moved, a neat appearance were even after 
administration of sufficiently high doses of the drug – 5.0 ml/kg and 6.3 ml/kg of body weight 
of the animal.
In animals receiving the drug in low doses (2.0 and 2.5 ml/kg), clinical signs of intoxication 
were not observed at all. No cases of death of rats were noted, as evidenced by the data presented 
in Table 2.
Table 2
Acute toxicity study of “Argocide” preparation in experiments on white mature rats with intramuscular 
injection
Animal sex
Doses of the Argocide, ml/kg
2.0 2.5 3.16 3.98 5.0 6.3
Female 0/2* 0/2 0/2 0/2 0/2 0/2
Male 0/2 0/2 0/2 0/2 0/2 0/2
Note: * – the ratio of the number of dead animals to the number of animals in the group by the indicated dose of the drug
Among the animals of the control group, after intramuscular introduction of “Argocide” 
death was not recorded, their behavioral and vegetative functions are unchanged. All control ani-
mals (n=6) were active, had smooth hair and clean skin.
Weight of internal organs. A study was made of the absolute mass of the internal organs 
of sexually mature rats, which are euthanized 14 days after a single injection of the study drug, 
as well as calculations of the relative mass of internal organs in g per 100 g of body weight of 
the animal. The absolute mass of the internal organs in the mature rats of the experimental 
groups did not undergo actual changes in relative to the corresponding index in the rats of the 
control group. The rats of the control group were examined for comparison with the rats of the 
test group at the corresponding (identical) observation times. This allowed to provide averaged 
data for all organs in animals receiving different doses of the drug. The results are shown 
in Table 3.
The relative mass of the internal organs in the mature rats of the experiment groups in 
obtaining the highest studied doses (3.98, 5.0, and 6.3 ml/kg) did not differ significantly from 
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Macroscopic studies. Pathomorphological examination of organs and tissues of white ma-
ture rats of both sexes was conducted, which survived and was euthanized after 14 days of obser-
vation. The animals were once administered the drug “Argocide” in a dosage form solution for 
intracisternal administration in various doses.
Table 3
Absolute mass (M±m, g) of the internal organs of mature white rats subjected to euthanasia 14 days after 








Heart 0.89±0.01 0.90±0.01 0.87±0.01 0.90±0.01
Lungs 1.31±0.02 1.29±0.2 1.20±0.2 1.24±0.1
Liver 10.54±1.30 10.34±1.1 10.13±1.2 9.86±0.8
Spleen 1.27±0.02 1.19±0.03 1.18±0.03 1.19±0.3
Kidneys 2.29±0.07 2.16±0.1 2.14±0.08 2.15±0.09
Table 4
The relative mass of internal organs (g/100 g of body weight M±m) in white rats (n=6) after a single 
intramuscular injection of the preparation “Argocide” at a dose of 6.3 ml/kg, and rats of the control group 






Heart 0.46±0.01 0.45±0.01 0.45± 0.01
Lungs 0.66± 0.03 0.66±0.03 0.63±0.02
Liver 5.35±0.15 5.25±0.2 5.01± 0.24
Spleen 0.65±0.01 0.61±0.01 0.62±0.02
Kidneys 1.17±0.03 1.10±0.01 1.10±0.04
According to the external examination of animals, no signs of pathological changes in 
their condition were found, hair and skin were clean, the subcutaneous layer of fatty tissue was 
moderately expressed, no mucous membranes and skin lesions were observed. Eyes, nose, lips, 
mouth, anal opening and external genital organs had a normal structure in all animals of exper-
imental groups.
When the sexually mature animals were autopsied, the serous membranes of the abdomi-
nal, pleural and pericardial cavity were smooth, shiny, without signs of damage or inflammation, 
the amount of free serous fluid in the cavities is not increased. The brain, organs of the abdominal 
cavity, as well as the small pelvis are located without deviations from the norm, the colour and 
consistency of them were not changed; organs of the chest cavity (lungs, heart) had the usual colour 
and blood filling. Myocardium had viscoelasticity consistency in all animals of all groups, homo-
geneous on the cut, dark red (cherry) colour. Endocardium of the atria and ventricles was smooth, 
shiny, the trabecular relief of the ventricular cavity is clear. Heart valves were thin, elastic. Aortic 
wall of usual thickness, elastic, with a brilliant intima of a whitish colour. In animals that were 
euthanized, lung tissue is not uniform, loose consistency.
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The surface of the mucosa of the larynx, trachea and large bronchi was not changed, covered 
with a small amount of mucus, the lumen of these organs was free.
In the gastrointestinal tract of all rats of the experimental and control groups were observed 
no alternative changes or ulcers. The mucous membrane of the stomach had pronounced crypts, 
without swelling, without damage to the erosive or ulcerative nature.
The liver was of ordinary size, its capsule was smooth, shiny, the liver tissue was uniform, 
dense-elastic, in a section of reddish-red color. The pancreas was located in the mesentery of 
the duodenum, a lobate structure, its tissue was whitish-yellow, with no signs of damage and 
inflammation.
Kidneys were of usual shape and size. Their surface was covered with an unaltered dense 
fibrous capsule, which was easily separated from the parenchyma of the organ. The tissue of the 
kidneys was of elastic consistency, with no signs of structural changes, the cortical and cerebral 
layers of the organ were clearly defined on the cut. Bowls are not dilated, their mucous membranes 
are thin, smooth, shiny, pale pink.
The wall of the bladder is thin, elastic, pale pink in the cavity of a small amount of trans-
parent urine.
The state of endocrine organs of rats – thyroid gland, adrenal glands had no visible devi-
ations from the norm. Adrenals were of usual size and shape, on a cut of yellow colour. Thyroid 
gland of usual size and shape, lobate structure, on a section of brownish-red colour. The macro-
scopic structure of the thymus and spleen was the same as that of the control animals, with no signs 
of alternative changes, hemocirculatory disorders of atrophy and hypertrophy.
6. Discussion
Pharmacological and toxicological results of studies of drugs and compounds of silver are 
widely represented in the scientific literature. The authors [21] give data on the toxic properties of 
Argumistin veterinary medicinal product with a mass content of colloidal silver of 10 and 50 μg/ml, 
in a dosage form a solution for local and internal use. It has been established that Argumistin 
is a low-risk chemical substance after introduction into the stomach by laboratory animals ac-
cording to the classification of the average lethal dose. With prolonged enteral administration, 
preparations at doses of 5 ml/kg did not exert any noticeable inhibitory effect on the overall state 
of white non-linear mice.
N. N. Shkil and co-authors determined the parameters of subchronic toxicity of the sil-
ver-containing drug Argovit on laboratory animals [22]. For white mice, the cumulation coefficient 
was 24.15, for white rats – 16.1, which made it possible to classify the test drug as non-cumulative. 
With the prolonged administration of increasing toxic doses of Argovit to white rats, they found no 
significant changes in the immunobiochemical parameters of blood serum. During the entire study 
period, no mortality of laboratory animals was detected, as well as violations of the function of 
their gastrointestinal tract.
N. S. Ponomar with co-authors studied the acute toxicity of a new drug of ionized silver. 
The obtained results testified to the absence of any influence of even the maximum possible dos-
es of the study drug on behavioral, neuromuscular and vegetative reactions in rats, as well as the 
lethality of animals in both enteral and parenteral administration. LD50 of a silver preparation in 
this connection was not established, and the authors of the study drug are classified as low-toxic 
and safe [23]. 
A dose-dependent assessment of the toxicity of silver nanoparticles in Wistar rats in 
vivo is presented by D. K. Tiwari, T. Jin, J. Behari. The studies are devoted to the study of 
the effect of various doses of silver nanoparticles on rats. Four different doses (4, 10, 20 and 
40 mg/kg) were administered intravenously. It has been shown that silver nanoparticles in dos-
es (<10 mg/kg) are safe for biomedical applications and have no side effects, but at high doses 
(>20mg/kg) are toxic [24].
Ukrainian scientists have studied the acute toxicity of silver nanoparticles in a colloi-
dal solution. It was found that LD50, when administered intraperitoneally to male and female 
BALB mice, was 34.53±3.87 mg/kg and 22.17±2.36 mg/kg, respectively. The authors classify 
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silver nanoparticles as substances of the third toxicity class “moderately toxic compounds” 
according to the K. K. Sidorov classification (1973), and LD50 when administered intravenously 
to white non-linear mice for males and females is 83.2±10.93 mg/kg and 99.92±11.71 mg/kg, 
respectively [25].
Park K., Park E. J., Chun I. K. et al. investigated the bioavailability and toxicokinetics 
of silver-coated nanoparticles coated with citrate. Male rats were administered orally or in-
travenously 1 or 10 mg/kg silver nanoparticles. It was found that, after oral administration, 
the concentration of silver nanoparticles in blood was very low. However, after injection of 
the tail vein, a high level of silver in the blood was detected. When silver nanoparticles were 
administered to rats at a dose of 1 mg/kg, the silver concentration in the blood was significant-
ly increased 10 min after injection; the level subsequently decreased. In rats receiving silver 
nanoparticles at a dose of 10 mg/kg, an elevated level of concentration persisted during the 
experimental period. It is noted that silver nanoparticles accumulate in the liver, lungs and 
kidneys [26].
Souza L. R. R., da Silva V. S., Franchi L. P., de Souza T. A. J. pay attention to the need for 
in-depth study of the mechanism of cytotoxicity of some silver nanoparticles, as well as possible 
toxic effects [27].
As part of the pre-clinical study of the combined veterinary drug “Argocide” containing 
a silver compound, a study was conducted of the acute toxicity of the drug form, a solution 
for intracisternal administration. Doses were calculated for the dosage form, and not for the 
active pharmaceutical ingredient. It should be noted that such studies are being conducted for 
the first time.
According to the analysis of the data obtained (Table 1), it was determined that such integral 
indices of vital activity of animals as mass and body temperature did not experience significant 
individual fluctuations during the 14 days of observation after a single intramuscular injection of 
the drug “Argocide”. At the same time, a physiological increase in body weight in animals was 
noted. The animals of the experimental and control groups gained weight in accordance with the 
physiological norm.
A study of the acute toxicity of the preparation “Argocide” in experiments on white mature 
rats with intramuscular introduction (Table 2) showed that among the animals of the control group, 
when intramuscular “Argocide” was administered, death was not recorded, their behavioural and 
vegetative functions were unchanged.
With external examination, autopsy and macroscopic examination of rats of both sexes 
who received Argocid once, the solution for intracisternal administration in different doses in 
the range from 2.0 ml/kg to 6.31 ml/kg of body weight, after 14 days of the introduction, there 
were no signs of a violation of hemocirculation in the tissues of the heart, lungs, stomach and 
small intestine.
In groups of control and experimental animals, no alternative, inflammatory and hemody-
namic disorders in various organs and tissues were detected.
Thus, the research on determining the value of the average lethal dose (LD50) of the 
veterinary drug “Argocide”, a solution for intracisternal administration, with intramuscular 
single administration to white mature rats is impossible because of the absence of animal death 
even when the drug is administered in doses exceeding 5,0 ml/kg. The introduction of higher 
doses is considered inexpedient. This circumstance makes it possible to classify the prepara-
tion “Argocide”, a solution for intracisternal administration, considering the classification of 
chemical substances according to the degree of danger, to practically non-toxic preparations 
(V class).
7. Conclusions
1. The acute toxicity of the intramammary veterinary drug under the conventional name 
“Argocide” was carried out, in the dosage form – a solution for intracisternal administration.
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2. Tests were carried out on white non-linear sexually mature rats of both sexes with intra-
muscular injection in different doses – from 2.0 to 6.3 ml/kg.
3. It has been established that such integral indices of vital activity of animals as mass and 
body temperature did not experience significant individual fluctuations during the 14 days of ob-
servation after a single intramuscular injection of the “Argocide”.
4. It was noted that after intramuscular administration of the preparation “Argocide” 
at doses of 3.16 ml/kg body weight of the animal and above, certain clinical signs of in-
toxication appeared in the rats. However, 3 days after the intramuscular application of the 
drug “Argocide”, no clinical signs of intoxication were observed even with the adminis-
tration of sufficiently high doses of the drug – 5.0 ml/kg and 6.3 ml/kg of body weight of 
the animal.
5. Animals receiving the drug in low doses (2.0 and 2.5 ml/kg) had no clinical signs of in-
toxication at all. No cases of death of rats were noted.
6. Conducting studies to establish the value of the average lethal dose (LD50) of the 
veterinary drug “Argocide” with intramuscular single administration to white mature rats is 
impossible because of the absence of animal death even when the drug is used in doses ex-
ceeding 5.0 ml/kg.
7. This experiment allows us to refer veterinary drug “Argocide”, a solution for intracister-
nal administration, considering the classification of chemical substances according to the degree of 
danger, to practically non-toxic preparations (V class).
8. Analysis of the results of the conducted studies indicates the relative harmlessness of the 
potential drug for veterinary medicine and allows to foresee that the “Argocide” can be classified 
as low-risk substances, which justifies the expediency of its further study and introduction into 
practice.
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